Inflammatory Bowel Disease Televisits, Added RSV Risks, and More in the August Issue of AJG

The August issue of AJG includes articles on IBD, including the use of telehealth and added risks for RSV hospitalization, and the updated nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD).

The Rising Costs of Alcohol-Associated Liver Disease and More in the February Issue of AJG

A modeling study projecting the economic and social burden of alcohol-associated liver disease by 2040 is featured in the February 2024 issue of AJG, just one month after the new ACG Clinical Guideline on Alcohol-Associated Liver Disease

Studies on Higher Infliximab Concentrations in IBD, Opioid-Related Constipation and More in the November Issue of AJG

The November issue of AJG highlights new clinical science and reviews including additional colonoscopy quality measures, higher infliximab concentrations in IBD patients with higher visceral adipose tissue (VAT), an automated tissue systems pathology test for Barrett’s esophagus, and opioid-related constipation.

New “Guide to the Guidelines” Publication Offers Practical Advice for Implementing ACG Clinical Guidelines

This new publication, introduced at the ACG 2023 Annual Scientific Meeting, provides clinical vignettes to demonstrate the practical application of ACG Clinical Guidelines.

April Issue of AJG Discusses Colorectal Cancer Risk Factors, H. pylori Infection, and Crohn’s Therapies

The April issue of The American Journal of Gastroenterology highlights new clinical science, including an examination of changes in lifestyle habits and risk of colorectal cancer

February Issue of AJG Features New Guideline on Acute Lower GI Bleeding

The February issue of The American Journal of Gastroenterology features a new ACG Clinical Guideline on Acute Lower GI Bleeding, a common reason for hospitalization in digestive diseases, which can be challenging to assess and triage.

Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors (PPIs)

Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.